NO20052244L - Enantioselektiv fremgangsmate for fremstilling av begge enantiomerene av 10,11- dihydro-10-hydroksy-5H-dibenzo[b,f]- azepin-5-karboksamid og nye krystallformer derav - Google Patents

Enantioselektiv fremgangsmate for fremstilling av begge enantiomerene av 10,11- dihydro-10-hydroksy-5H-dibenzo[b,f]- azepin-5-karboksamid og nye krystallformer derav

Info

Publication number
NO20052244L
NO20052244L NO20052244A NO20052244A NO20052244L NO 20052244 L NO20052244 L NO 20052244L NO 20052244 A NO20052244 A NO 20052244A NO 20052244 A NO20052244 A NO 20052244A NO 20052244 L NO20052244 L NO 20052244L
Authority
NO
Norway
Prior art keywords
hydroxy
crystal forms
carboxamide
enantiomers
dihydro
Prior art date
Application number
NO20052244A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052244D0 (no
Inventor
Gottfried Sedelmeier
Sabine Pfeffer
Fritz Blatter
Christian Mathes
Dominique Grimler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20052244D0 publication Critical patent/NO20052244D0/no
Publication of NO20052244L publication Critical patent/NO20052244L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/22Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
    • C07D223/24Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0046Ruthenium compounds
    • C07F15/0053Ruthenium compounds without a metal-carbon linkage

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20052244A 2002-10-07 2005-05-06 Enantioselektiv fremgangsmate for fremstilling av begge enantiomerene av 10,11- dihydro-10-hydroksy-5H-dibenzo[b,f]- azepin-5-karboksamid og nye krystallformer derav NO20052244L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0223224.7A GB0223224D0 (en) 2002-10-07 2002-10-07 Organic compounds
PCT/EP2003/011034 WO2004031155A1 (en) 2002-10-07 2003-10-06 ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF BOTH ENANTIOMERS OF 10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ [b,f]AZEPINE-5-CARBOXAMIDE AND NEW CRYSTAL FORMS THEREOF

Publications (2)

Publication Number Publication Date
NO20052244D0 NO20052244D0 (no) 2005-05-06
NO20052244L true NO20052244L (no) 2005-07-07

Family

ID=9945425

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052244A NO20052244L (no) 2002-10-07 2005-05-06 Enantioselektiv fremgangsmate for fremstilling av begge enantiomerene av 10,11- dihydro-10-hydroksy-5H-dibenzo[b,f]- azepin-5-karboksamid og nye krystallformer derav

Country Status (20)

Country Link
US (1) US20060142566A1 (https=)
EP (1) EP1551808A1 (https=)
JP (1) JP2006504710A (https=)
KR (1) KR20050071549A (https=)
CN (2) CN1703404A (https=)
AR (1) AR041544A1 (https=)
AU (1) AU2003276055B2 (https=)
BR (1) BR0315113A (https=)
CA (1) CA2501237A1 (https=)
EC (1) ECSP055738A (https=)
GB (1) GB0223224D0 (https=)
HK (1) HK1079790A1 (https=)
MX (1) MXPA05003737A (https=)
NO (1) NO20052244L (https=)
PE (1) PE20040686A1 (https=)
PL (1) PL376379A1 (https=)
RU (1) RU2005114350A (https=)
TW (1) TW200413324A (https=)
WO (1) WO2004031155A1 (https=)
ZA (1) ZA200502561B (https=)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0303615D0 (en) * 2003-02-17 2003-03-19 Novartis Ag Use of organic compounds
GB0425320D0 (en) 2004-11-17 2004-12-22 Johnson Matthey Plc Diamines
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0515690D0 (en) 2005-07-29 2005-09-07 Portela & Ca Sa Asymmetric catalytic reduction
GB2437078A (en) 2006-04-11 2007-10-17 Portela & Ca Sa 10-Acyloxy-5H-dibenzo[b,f]azepine-5-carboxamides & their asymmetric hydrogenation to the chiral 10,11-dihydro derivatives
JP5172124B2 (ja) * 2006-09-29 2013-03-27 関東化学株式会社 2位に置換基を有する光学活性キヌクリジノール類の製造方法
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
WO2011045648A2 (en) * 2009-10-12 2011-04-21 Matrix Laboratories Limited Process for preparing (s)-(-)-10-acetoxy-10,11-dihydro-5h-dibenz[b,f]azepine-5-carboxamide and its esters thereof
EP2383261B1 (en) 2010-04-23 2013-09-04 Euticals GmbH Process for the asymmetric hydrogenation of ketones
CN102250005B (zh) * 2010-05-19 2015-04-08 浙江九洲药物科技有限公司 艾利西平的制备方法
US9346760B2 (en) 2011-03-08 2016-05-24 Jubilant Life Sciences Limited Process for the preparation of (S)-(+)- or (R)-(-)-10-hydroxy dihydrodibenz[B,F]azepines by enantioselective reduction of 10,11-dihydro-10-OXO-5H-dibenz[B,F]azepines and polymorphs thereof
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
WO2013167985A1 (en) * 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
EP2852569B1 (en) 2012-05-23 2020-10-14 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9498461B2 (en) 2012-05-23 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
CN104364231A (zh) 2012-09-08 2015-02-18 塞利克斯比奥私人有限公司 用于治疗炎症和脂质异常的组合物和方法
US20150232426A1 (en) 2012-09-26 2015-08-20 Ranbaxy Laboratories Limited Process for the preparation of oxcarbazepine and its use as intermediate in the preparation of eslicarbazepine acetate
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
EP3004049B1 (en) 2013-06-04 2018-09-05 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
EP3016961B1 (en) * 2013-07-01 2017-11-15 Boehringer Ingelheim International GmbH Novel ruthenium catalysts and their use for asymmetric reduction of ketones
CN103483257A (zh) * 2013-09-06 2014-01-01 江苏同禾药业有限公司 一种亚氨基芪的合成方法
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
JP6698643B2 (ja) 2014-09-29 2020-05-27 セリックス バイオ プライヴェート リミテッドCellix Bio Private Limited 多発性硬化症の治療のための組成物及び方法
AU2014414316B2 (en) 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CA2973178C (en) 2015-01-06 2022-11-01 Cellix Bio Private Limited Bupivacaine derivatives and their use in the treatment of inflammation and pain
EP3064490A1 (en) 2015-03-06 2016-09-07 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Improved process for the preparation of eslicarbazepine and eslicarbazepine acetate
CN107033079B (zh) * 2016-10-17 2020-07-28 扬子江药业集团北京海燕药业有限公司 醋酸艾司利卡西平的制备方法
CN112679433B (zh) * 2019-10-18 2024-05-24 浙江九洲药业股份有限公司 一种艾利西平的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT101732B (pt) * 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
IL146952A0 (en) * 1999-06-15 2002-08-14 Rhodia Chimie Sa Sulphonylamides and carboxamides and their use in asymmmetical catalysis
JP2004526706A (ja) * 2001-02-12 2004-09-02 テバ ファーマシューティカル インダストリーズ リミティド オクスカルバゼピンの新しい結晶形態及びそれらの調製方法

Also Published As

Publication number Publication date
MXPA05003737A (es) 2005-06-17
CN1703404A (zh) 2005-11-30
BR0315113A (pt) 2005-08-23
TW200413324A (en) 2004-08-01
WO2004031155A1 (en) 2004-04-15
AU2003276055B2 (en) 2008-01-03
AU2003276055A1 (en) 2004-04-23
CN101062932A (zh) 2007-10-31
US20060142566A1 (en) 2006-06-29
KR20050071549A (ko) 2005-07-07
ECSP055738A (es) 2005-07-06
RU2005114350A (ru) 2006-01-20
PE20040686A1 (es) 2004-10-29
PL376379A1 (en) 2005-12-27
HK1079790A1 (zh) 2006-04-13
GB0223224D0 (en) 2002-11-13
CA2501237A1 (en) 2004-04-15
AR041544A1 (es) 2005-05-18
JP2006504710A (ja) 2006-02-09
ZA200502561B (en) 2006-02-22
NO20052244D0 (no) 2005-05-06
EP1551808A1 (en) 2005-07-13

Similar Documents

Publication Publication Date Title
NO20052244L (no) Enantioselektiv fremgangsmate for fremstilling av begge enantiomerene av 10,11- dihydro-10-hydroksy-5H-dibenzo[b,f]- azepin-5-karboksamid og nye krystallformer derav
EP2598482B1 (en) Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
EP2598480B1 (en) Cyclopropylamine derivatives useful as lsd1 inhibitors
TWI868528B (zh) Tyk2抑制劑之生產方法
MX2011002705A (es) Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso.
TW200621262A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
MX2012010658A (es) Compuestos de anillo espiro tetraciclico como moduladores de beta-secretasa.
AR040489A1 (es) Compuestos derivados de 3-fenil-propionamido, 3-fenil-acrilamido y 3-fenil-propinamido, su uso para la elaboracion de medicamentos, un proceso para elaborar los compuestos y medicamentos que los contienen
Taha et al. Synthesis of potent urease inhibitors based on disulfide scaffold and their molecular docking studies
RU2719599C2 (ru) Соединения 6, 7-дигидро-5H-пиразоло[5,1-b][1,3]оксазин-2-карбоксамида
WO2022192562A1 (en) Usp30 inhibitors and uses thereof
DE502005010342D1 (en) Substituierte cyclohexylessigsäure-derivate
WO2023183908A1 (en) Tyk2 inhibitor synthesis and intermediates thereof
NO20064752L (no) N-piperidinderivater som CCR3-modulatorer
CN111303046A (zh) 含手性羟亚甲基结构的联苯二芳基嘧啶类衍生物及其制备方法和用途
CN111065619B (zh) (E)-α,β-不饱和酰胺化合物及其制备方法和用途
EP3720855A1 (en) Imidazopyridine derivatives and the use thereof as medicament
ATE283838T1 (de) Wirksame derivate der valproinsäure zur behandlung von neurologischen und psychotischen störungen, und ein verfahren zu ihrer herstellung
KR20130141505A (ko) (6r)-테트라하이드로비옵테린 하이드로클로라이드의 제조 방법
PL1761480T3 (pl) Inhibitory mao-b
CN109890798A (zh) 用于治疗cns病症的羟基去甲氯胺酮衍生物
Ramudua et al. Synthesis, spectral characterization and bioactivity evaluation of sulfonamide derivatives of p-nitrobenzene sulfonylchloride
WO2015129603A1 (ja) 活性化血液凝固第X因子(FXa)阻害剤の高純度結晶
TWI481612B (zh) (6r)-四氫生物喋呤鹽酸鹽的製備方法
JP2010116322A (ja) ベータセクレターゼ蛋白質の酵素阻害物質とそれを用いた予防薬

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application